Opendata, web and dolomites

TrojanDC SIGNED

TrojanDC

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TrojanDC project word cloud

Explore the words cloud of the TrojanDC project. It provides you a very rough idea of what is the project "TrojanDC" about.

size    combination    balanced    shown    critical    therapy    car    antigen    health    consistently    innovative    roche    inducing    develops    approx    proprietary    maximizing    viral    merck    trojandc    fits    antigens    something    delivers    markets       reprogramming    114    bms    gene    market    start    lose    price    re    heterogeneous    shortcomings    swedish    proof    demand    robustly    global    resistance    350k    personalized    vector    effector    strategy    oncology    uses    cancer    seasoned    eradicate    immune    effectiveness    educates    injection    presenting    performing    genes    tumor    sound    transcription    commercialization    overhaul    2024    vivo    paradigm    grant    team    founded    diversity    fastest    reliably    entrepreneurs    data    limited    immunotherapies    cagr    named    asgard    anti    players    cell    dendritic    instrument    immunogenic    despite    patients    locked    cells    sme    tumoral    form    urgent    therapeutics    chances    14    company    costing    acquisitions    keen    technologies    shifting    efficacy    scientists    patient    immunotherapy   

Project "TrojanDC" data sheet

The following table provides information about the project.

Coordinator
ASGARD THERAPEUTICS AB 

Organization address
address: REVINGEGATAN 19C 1203
city: LUND
postcode: 223 59
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASGARD THERAPEUTICS AB SE (LUND) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Asgard Therapeutics, a Swedish start-up company, was founded based on a unique proprietary in vivo cell reprogramming technology. This paradigm-shifting gene therapy has the unique potential to overhaul the cancer immunotherapy market.

Our gene therapy, named TrojanDC, delivers immune-genes into the tumor and re-educates cancer cells to become anti-tumor immune cells. It uses a viral vector to deliver a unique combination of three critical transcription factors (genes) through intra-tumoral injection. The transcription factors make cancer cells become antigen-presenting dendritic cells. These immunogenic cells present their own diversity of tumor-specific antigens to effector immune cells, reliably and robustly inducing immune responses that eradicate the heterogeneous tumor.

Cancer remains a major health challenge. Currently available immunotherapies show strong effectiveness only in a limited number of patients, and often lose their efficacy as the tumor develops resistance. In addition, immunotherapies come with high price (e.g. CAR-T cell approach costing approx. € 350k/patient). Despite these shortcomings, the global immune-oncology market is one of the fastest growing therapeutics markets (€114.6 B by 2024 with a CAGR of 14.3%). Large players like BMS, Merck and Roche have shown to be keen on acquisitions of high-potential technologies. There is thus an urgent need and high demand for innovative cost-effective immunotherapies consistently effective in a broader range of cancer patients – something that Asgard Therapeutics will deliver with TrojanDC in the form of a personalized and highly specific immune therapy using a ‘one-size-fits-all’ approach.

With in-vivo proof-of-concept data already obtained and a balanced team of high-performing scientists and seasoned entrepreneurs, Asgard Therapeutics has locked up key factors towards maximizing its chances of success. This SME instrument grant will ensure a sound strategy towards commercialization of TrojanDC.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TROJANDC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TROJANDC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

B2BMarketplace (2019)

The first B2B marketplace for Fast Moving Consumer Goods, connecting all brand manufacturers and retailers globally

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More